Organoids paired with nanoparticles could offer new insights into cancer treatment, improving predictions of drug efficacy ...

DelveInsight's CLK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Lung adenocarcinoma remains one of the most challenging cancers to diagnose accurately, with pathologists spending countless hours examining tissue ...

Researchers have successfully demonstrated that advanced generative AI (GenAI) models can accurately assess lung ...

Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non–small cell lung cancer. We aimed to investigate whether no mediastinal LND was ...

The authors present a histologic and immunohistochemical study of a case of primary thymic adenocarcinoma, an exceedingly rare cancer for which there is little genetic data.

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these therapies, and a surge in the number of CLK ...

The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior positive feedback.

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company to request urgent talks.

Patients with BCG Unresponsive Papillary disease, face a life changing and life-threatening prospect of a total radical cystectomy, as well as the danger of the disease progressing from non-muscle ...

The accelerated approval was based on the results of the eNRGy trial of 64 patients with NRG1-positive non–small cell lung cancer and 30 patients with NRG1-positive pancreatic adenocarcinoma.